Ocugen, Inc.

Pursuing Innovative Ocular Biotherapeutics

Press Releases

Keyword Search

November 27, 2020
CEO Dr. Shankar Musunuri to be Featured as a Panelist at Xconomy’s Xcelerating Life Sciences Virtual Event Discussing The Promise of Cell & Gene Therapies
MALVERN, Pa., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri , Chairman, CEO, and Co-Founder of Ocugen, will
Additional Formats
PDF Version
October 22, 2020
CEO Dr. Shankar Musunuri to Discuss the Importance of Gene Therapy Strategic Partnerships at 4th Annual Gene Therapy for Rare Disorders Europe Conference
MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced Dr. Shankar Musunuri , Chairman, CEO, and Co-Founder of Ocugen, will
Additional Formats
PDF Version
October 6, 2020
Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200
Paves the way towards getting OCU200 in the clinic by 1H 2022 as planned MALVERN, Pa., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. , (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today
Additional Formats
PDF Version
Displaying 1 - 10 of 26